Endocrine Abstracts

Introduction: Thyroid nodule is a frequent condition, being diagnosed in up to 70% of subjects who had undergone thyroid ultrasound. Around 90-95% of them became being benign and, if the do not cause compressive symptoms or esthetical problems, they do not need specific therapy, only clinical follow up. Traditionally, thyroidectomy has been the main therapeutic option in these cases. Radiofrequency and ethanol ablations are recently introduced non-invasive therapies that permi...

TSH-secreting pituitary adenomas are a rare cause of hyperthyroidism. The diagnosis should be considered in all hyperthyroid patients, especially those with a diffuse goiter and no extrathyroidal manifestations of Graves’ disease. Most TSH-secreting adenomas secrete only TSH. Most patients have the typical symptoms and signs ofhyperthyroidism (eg, palpitations, tremor, heat intolerance), but a few patients have mild or even no hyperthyroid symptoms. Other clinical feature...

Pituitary adenomas (PAs) account for 15-20% of intracranial tumors. PA with a cystic component are characterized in the MRI by a sellar, symmetrical, round or ovoid mass that enhances on T1- or T2-weighted images but does not concentrate gadolinium. We present the case of a 48-year-old man who in a headache study by Neurology requested a CT scan showing a cystic pituitary macroadenoma of 1.25cm confirmed by pituitary MRI. In the initial analysis, the pituitary function was pre...

Introduction: Non-functioning pituitary adenomas are relatively common. A large number of these tumors are asintomathic pituitary microadenomas, that are increasingly detected because of sensitive imaging techniques improves. Those tumors that require treatment are generally macroadenomas and come to medical attention because of mass effect (visual field defects, headache, …) and/or hypopituitarism.Objective: To assess non-functioning pituitary ade...

Introduction: Pituitary adenomas are considered to be benign tumors that are diagnosed by its sympthoms (secondary to compression or hormonal secretion) or incidentally in an imaging technique performed because of another reason. ‘Silent’ somatotrophinomas are very rare. This type of adenoma is typically large and despite it presents with mild or no acromegalic features it usually develops hormone secretion.A case report: A 29-year-old spanish ...

Introduction: Stroke is the second cause of death in the world and the first cause of disability. It is also the second cause of Diabetes-related death. The success of reperfusion therapies is time-dependent, with most delays being patient-related. We investigated the response to stroke in diabetic patients (DM), as their risk of stroke is increased by 1,8-6 times.Material and Methods: Consecutive patients with acute stroke or transient ischemic attack w...

Introduction: In most patients with familial history of pheochromocytoma/paraganglioma, leads in the majorty of cases to a postive genetic testing for mutations, and what’s more in those patients with no familial antecedents, about 10–25% carry a mutation in one related gene. In these cases other aspects like, bilaterality, multiplicity or location must be taken into account.Objective: The objective of the study was to discuss the importance of...

Introduction: Prolactinomas are the most common tumors among functional pituitary adenomas and they constitute 40% of all pituitary tumors. Dopamine agonists (DA) are considered the primary treatment of prolactinoma. DA can lead to complete remission (including eradicacion of the tumor), allowing discotinuation of treatment. So far, there aren’t clinical criteria with sufficient predictive value for long-term remission.Objective: To assess the effec...

Introduction and Objective: Flash glucose monitoring is a form of interstitial glucose monitoring and it is indicated in patients with diabetes mellitus.The objetive of the study was to assess the effect of introducing flash glucose monitoring in adults with diabetes with respect to change in hemoglobin A1c (HbA1c).Material and methods: Prospective observational study of adults with diabetes in our center, in whom a prescription for a flash glucose monit...

Introduction: Dulaglutide (Trulicity®) is a long-acting GLP-1 agonist that received US Food and Drug Administration (FDA) approval in 2014. Dulaglutide is a large sized molecule, which limits its renal clearance. This allows for once weekly dosing; which might improve patient compliance significantly. Extensive Phase III study data have been published with regard to dulaglutide, much of which was part of the AWARD studies, which provide evidence for its use in ...